trending Market Intelligence /marketintelligence/en/news-insights/trending/zgvpwgycnjqhhs4osfoyhg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie ordered to pay $3M in AndroGel case

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AbbVie ordered to pay $3M in AndroGel case

AbbVie Inc. has been ordered to pay more than $3 million to Jesse Mitchell, who claimed to have suffered a heart attack because the company misrepresented the risks of AndroGel, Reuters reported March 26.

A federal jury in Chicago stated that the company was not strictly liable and had not falsely marketed the testosterone replacement drug, but noted that it had acted negligently. The jury awarded the Oregon resident $200,000 in compensatory damages and $3 million in punitive damages.

AbbVie, which is facing 4,510 cases across the U.S. over injuries blamed on the drug, expressed its disappointment with the verdict and plans on appealing the decision, Reuters reported, citing a company statement.

In December 2017, U.S. District Judge Matthew Kennelly reversed a $150 million verdict in favor of Mitchell, stating that the findings of the jury that held the company responsible were "logically incompatible."

AbbVie picked up a win in January when a federal jury found AbbVie's AndroGel not liable for the pulmonary embolism of Arizona resident Robert Nolte.

North Chicago, Ill.-based AbbVie faced its first verdict against AndroGel in October 2017, when a jury placed a $140 million penalty to be paid to Jeffrey Konrad, who claims the drug caused him a heart attack. AbbVie has asked Kennelly to scrap this verdict due to inconsistencies during the trial.